Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Cash from Investing Activities: 2013-2025

Historic Cash from Investing Activities for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $91.0 million.

  • KalVista Pharmaceuticals' Cash from Investing Activities rose 97.36% to -$3.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$43.7 million, marking a year-over-year increase of 48.44%. This contributed to the annual value of $91.0 million for FY2025, which is 207.44% up from last year.
  • KalVista Pharmaceuticals' Cash from Investing Activities amounted to $91.0 million in FY2025, which was up 207.44% from -$84.7 million recorded in FY2024.
  • KalVista Pharmaceuticals' 5-year Cash from Investing Activities high stood at $91.0 million for FY2025, and its period low was -$147.7 million during FY2021.
  • For the 3-year period, KalVista Pharmaceuticals' Cash from Investing Activities averaged around $15.9 million, with its median value being $41.4 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 981.36% in 2021, then surged by 207.44% in 2025.
  • KalVista Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$147.7 million in 2021, then surged by 139.19% to $57.9 million in 2022, then decreased by 28.42% to $41.4 million in 2023, then crashed by 304.56% to -$84.7 million in 2024, then surged by 207.44% to $91.0 million in 2025.